Changing Causes of US Neurological Disease Mortality From 1999 to 2017
This study estimates neurological disease mortality rate trends in the US population from 1999 to 2017 as well as regionalized differences within the US.
Related Articles
Endocrine Society (ENDO)
Explore special articles published online first to coincide with presentations at the Endocrine Society (ENDO).
Endocrine Society (ENDO)
Explore special articles published online first to coincide with presentations at the Endocrine Society (ENDO).
Endocrine Society (ENDO)
Explore special articles published online first to coincide with presentations at the Endocrine Society (ENDO).
Endocrine Society (ENDO)
Explore special articles published online first to coincide with presentations at the Endocrine Society (ENDO).
Endocrine Society (ENDO)
Explore special articles published online first to coincide with presentations at the Endocrine Society (ENDO).
Endocrine Society (ENDO)
Explore special articles published online first to coincide with presentations at the Endocrine Society (ENDO).
Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy
This randomized clinical trial examines the efficacy and safety of intra-arterial tenecteplase in patients with successful endovascular therapy.
Hepatocellular Carcinoma Surveillance and Survival in an Asia-Pacific Cohort
This cohort study evaluates the association of hepatocellular carcinoma (HCC) surveillance with the survival of a large contemporary cohort of people with HCC identified from…
Influenza Activity, Environmental Conditions, and the Risk of Invasive Pneumococcal Disease
This case-crossover study evaluates the short-term associations of influenza activity and environmental exposures with invasive pneumococcal disease risk in temperate countries and examines the generalizability…
Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy
This case-control study examines the association of Listeria monocytogenes susceptibility with the receipt of daratumamab-based therapy in Canadian patients with multiple myeloma.